MGXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Metagenomi Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 10, 2026
$0.81+0.03 (+3.55%)
Close on Oct 19, 2026
- Market cap
- $30.57M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$2.2382 (−73.38%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Metagenomi Therapeutics, Inc. saw revenue fall 51.8% to $25.21M over fiscal 2025. Free cash flow was -$85.80M.
Revenue
$25.21M
-51.8% vs. a year earlier
Operating income
-$100.57M
TTM Q2 2026
Free cash flow
-$85.80M
TTM Q2 2026
EPS, diluted
-$2.49
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over fiscal 2025, balances at Jun 30, 2026
Valuation
- Market cap
- $30.57M
- P/E ratio
- –
- Price to sales
- 1.21
- Price to book
- 0.27
- Dividend yield
- –
- Free cash flow yield
- -280.65%
Fundamentals
- Revenue
- $25.21M
- Net income
- -$93.46M
- EPS, diluted
- -$2.49
- Free cash flow
- -$85.80M
- Book value per share
- $2.99
- Diluted shares
- 38M
Four years at a glance
Fiscal years 2022 to 2025 and trailing twelve months, USD
Revenue
–
Operating income
-$100.57M
Net income
-$93.46M
EPS, diluted
-$2.49
Free cash flow
-$85.80M
Reported periodTrailing twelve months